Investigating the Relationship Between Temporal Bone CT, Bone Density, and Hearing Loss in Otosclerosis Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
Sponsorİbrahim Emir Yeşil

About this trial

The goal of this observational case-control study is to evaluate the relationship between temporal bone computed tomography (CT) findings, bone mineral density (BMD), and audiological parameters in adults diagnosed with otosclerosis. The main questions it aims to answer are:

Is there a correlation between temporal bone CT density values and the severity of hearing loss in otosclerosis? Do bone mineral density and serum vitamin D levels differ between otosclerosis patients and individuals without otosclerosis? Researchers will compare patients diagnosed with otosclerosis to a control group without otosclerosis to determine if CT-based density variations are associated with disease severity and systemic bone metabolism markers.

Participants who have already had a temporal bone CT scan as part of their routine clinical evaluation will undergo:

Bone mineral density (BMD) assessment via dual-energy X-ray absorptiometry (DEXA) Serum vitamin D level measurement Audiological testing, including pure tone audiometry and speech discrimination tests This study aims to improve the diagnostic and prognostic understanding of otosclerosis by integrating imaging, metabolic, and audiological data.

Eligibility criteria

Qualifiers

Adults diagnosed with otosclerosis based on audiological and clinical assessment

Patients with available high-resolution CT scans and audiological data

Individuals who have undergone stapedectomy or stapedotomy surgery

Availability of bone mineral density and serum vitamin D data

Disqualifiers

History of primary metabolic bone diseases (osteoporosis, Paget's disease)

Use of medications affecting bone metabolism (bisphosphonates, corticosteroids)

History of chronic otitis media or prior ear surgeries

Patients who received head and neck radiotherapy

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

86 Participants
are grouped into 2 trial groups

Sponsors and collaborators

İbrahim Emir Yeşil

Lead sponsor

Hacettepe University

Sponsor institution